zintick
AXGN Axogen+31.5%Stock moveEarnings and guidance

Axogen Stock Jumps 31% After Q3 Revenue Rises 26% and Guidance Is Raised

The company raised its full-year 2026 revenue outlook to at least $290 million, or 29% growth, the same day it reported third-quarter results.

By Zintick Team · Editor: Kratik Mehta
Published

AXGN · Oct. 28, 2026
+31.5%
the session's move

Key points

  • Axogen shares rose 31.5% Wednesday, Oct. 28, to $49.25 as Q3 results were reported
  • Q3 revenue rose 26.2% to $75.8 million; full-year 2026 revenue guidance raised to at least $290 million
  • Cash and investments reached $350.1 million after a $225 million net-proceeds offering

Axogen (Nasdaq: AXGN) shares rose 31.5% on Wednesday, closing at $49.25 against a previous close of $37.46, as the company reported third-quarter 2026 results and raised its full-year revenue guidance. The S&P 500 ETF (SPY) rose 0.34% in the session, and volume ran at about 7.3 times its usual level.

The company disclosed the results in an 8-K filed before the market open, with the earnings press release attached as Exhibit 99.1.

Revenue growth and a raised outlook

Third-quarter revenue was $75.8 million, up 26.2% from $60.1 million a year earlier. Gross margin was 74.8%, compared with 76.6% in the third quarter of 2025. GAAP net income was $2.3 million, or $0.04 per share, compared with $0.7 million, or $0.01 per share, a year earlier. Adjusted net income was $13.1 million, or $0.21 per share, versus $6.1 million, or $0.12 per share, a year earlier.

For 2026, Axogen now expects full-year revenue of at least $290 million, growth of at least 29%, including at least $7 million from the BioCircuit acquisition.

Cash position after a stock offering

The company closed an upsized public offering of 5,646,500 shares, receiving $225 million in net proceeds. It used $200 million to fund the October 1 acquisition of BioCircuit Technologies, Inc., and reported cash, restricted cash and investments of $350.1 million as of Sept. 30, up from $113.4 million on June 30.

Prostate expansion

Axogen said it will begin prostate market development in 2027 based on clinical study outcomes, and will hold an investor call on Nov. 9, 2026.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

AXGN page →

Filings, figures and price history are on the Axogen page.